Agenus

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agenus reports robust Q4 earnings, advances immuno-oncology pipeline

Agenus showcased strong financials, progress in immuno-oncology pipeline, and durable responses in various cancers
Strategic partnerships and innovative R&D capabilities position the company well for future growth and development
Challenges in enrollment, differentiation, and managing immune-related toxicities are being actively addressed for continued success

Agenus (AGEN) reports progress in cancer treatment programs

Agenus (AGEN) showcased strong progress in its cancer treatment programs, with notable response rates and Fast Track Designation for a promising combination therapy.
While financials remained stable, the company faces challenges in maintaining response rates and successful study enrollments, requiring effective regulatory navigation and communication strategies.
Opportunities for Agenus include presenting at ASCO, expanding development programs, and attracting partnerships to drive further advancements in oncology treatments.

Agenus reports positive trial outcomes and strong regulatory strategy

Agenus is making significant progress in cancer treatment with positive trial outcomes and a strong regulatory strategy.
The company's commitment to innovation, patient quality of life, and managing side effects positions them well for future success.
Challenges include addressing analyst inquiries, enrollment in studies, and managing toxicities, but opportunities exist in partnerships and targeted treatment approaches.

Agenus reports robust earnings, eyes strategic partnerships for growth

Agenus Inc. demonstrated strong financial performance and progress in its BOT/BAL program.
While facing challenges in trial enrollment and funding, the company is focused on strategic partnerships.
Opportunities lie in upcoming data disclosures, potential BLA submissions, and product launches.

Agenus reports Q1 2024 financials, progresses BOT/BAL program for growth

Agenus navigates financial challenges with a focus on advancing the BOT/BAL program towards commercialization. Despite losses, the company's strategic initiatives position it for potential growth opportunities through milestone achievements and market expansion.

Agenus (AGEN) reports Q3 loss, advances cancer therapy innovations

Agenus (AGEN) is navigating financial challenges with a focus on advancing transformative cancer therapy and strategic partnerships.
Despite a net loss of $67 million, progress in BOT/BAL development and strategic initiatives position Agenus for future growth.
Opportunities in upcoming clinical studies and data readouts in 2025 underscore the company's commitment to innovation and patient care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109908&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Agenus Inc. (AGEN) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109877&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on Agenus Inc. (AGEN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / October 29, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109825&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Agenus Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024 - AGEN

NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Agenus securities between January 23, 2023, and July 17, 2024, inclusive (the "Class Period").

AGEN Investors Have Opportunity to Lead Agenus Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109783&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024 – AGEN

Investors can contact the law firm at no cost to learn more about recovering their losses

Agenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion.

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109730&wire=1 or contact Joseph E. Levi, Esq.

Class Action Filed Against Agenus Inc. (AGEN) - November 5, 2024 Deadline to Join - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109708&wire=1 or contact Joseph E. Levi, Esq.

Shareholders That Lost Money on Agenus Inc. (AGEN) Should Contact Levi & Korsinsky About Pending Class Action - AGEN

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109613&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Agenus Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AGEN

NEW YORK CITY, NY / ACCESSWIRE / October 28, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Agenus securities between January 23, 2023, and July 17, 2024, inclusive (the "Class Period").

AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Agenus securities between January 23, 2023, and July 17, 2024, inclusive (the "Class Period").

AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Agenus To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Agenus between January 23, 2023 and July 17, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). [You may also click here for additional information] NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Agenus Inc. ("Agenus" or the "Company") (NASDAQ: AGEN) and reminds investors of the November 5, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

LOS ANGELES, CA / ACCESSWIRE / October 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 23, 2023 and July 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 5, 2024.

Agenus Inc Is Being Sued For Violating Securities Laws And Impacted Shareholders Are Urged To Reach Out To The Schall Law Firm

NEW YORK , Oct. 23, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the "Class Period"), of the important  November 5, 2024 lead plaintiff deadline. So what: If you purchased Agenus securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit

NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Agenus Inc. (NASDAQ: AGEN).

Agenus Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before November 5, 2024 to Discuss Your Rights – AGEN

NEW YORK, NY / ACCESSWIRE / October 23, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109444&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of Agenus Inc.(AGEN) of a Class Action Lawsuit and an Upcoming Deadline

LOS ANGELES, CA / ACCESSWIRE / October 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 23, 2023 and July 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 5, 2024.

The Schall Law Firm Encourages Investors To Join A Securities Fraud Case Against Agenus Inc.

NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Agenus securities between January 23, 2023, and July 17, 2024, inclusive (the "Class Period").

AGEN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”), of the important November 5, 2024 lead plaintiff deadline.

RLF, TOP RANKED GLOBAL COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important November 5 Deadline in Securities Class Action – AGEN

NEW YORK, NY / ACCESSWIRE / October 22, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109213&wire=1 or contact Joseph E. Levi, Esq.

Agenus Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - AGEN

NEW YORK CITY, NY / ACCESSWIRE / October 22, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Agenus securities between January 23, 2023, and July 17, 2024, inclusive (the "Class Period").

AGEN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Agenus Inc. Investors Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109070&wire=1 or contact Joseph E. Levi, Esq.

Agenus Inc. Class Action: Levi & Korsinsky Reminds Agenus Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 5, 2024 – AGEN

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=109009&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by November 5, 2024 Deadline to Join Class Action Against Agenus Inc.(AGEN)

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=108928&wire=1 or contact Joseph E. Levi, Esq.

Agenus Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN

NEW YORK, NY / ACCESSWIRE / October 21, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=108912&wire=1 or contact Joseph E. Levi, Esq.

News for Agenus Stock (AGEN)